Formation Bio stock
Private-market facts for current and former Formation Bio employees researching their stock.
Overview
AI-driven biopharmaceutical company that uses technology and data to accelerate the development and commercialization of new medicines.
Formation Bio outlook
For employees evaluating Formation Bio equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Formation Bio shares
Why shareholders consider selling
Shareholders in Formation Bio may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Formation Bio does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Formation Bio stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Formation Bio shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Formation Bio shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series D round and its reported $1B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Formation Bio shareholders
Exploring equity in Formation Bio often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Formation Bio most recently raised a Series D round in January 2024. The company was valued at $1B. Total funding raised to date is approximately $572M.
Lead investors in this round include Andreessen Horowitz and Sequoia Capital.
Investors
Industry
Similar private companies
Latest Formation Bio news
Frequently asked questions
- Is Formation Bio still a private company?
- Yes, Formation Bio is currently a private company.
- What is Formation Bio's latest funding round?
- Formation Bio's most recent known round is Series D, raised in January 2024.
- What is Formation Bio's valuation?
- Formation Bio's latest reported valuation is $1B.
- Who are the investors in Formation Bio?
- Notable investors include Andreessen Horowitz, Sequoia Capital.
- Can I sell my Formation Bio stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Formation Bio stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Formation Bio data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.